GlassScriptPhysician profile
Tanya C Bralley
NPI 1073667234
$6,729.25
in general payments reported to CMS, 2019-2025
51 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $881 · 2022: $1,238 · 2023: $1,848 · 2024: $1,347 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,090 · Long Term Medical Supply Or Device Loan: $299 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,089.75 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $221.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $883.05 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $708.62 | 2021-2025 | Opdivo, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $654.55 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Adaptive Biotechnologies Corporation | $281.75 | 2022-2023 | Clonoseq |
| Celgene Corporation | $268.39 | 2021-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $252.61 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Daiichi Sankyo INC. | $248.19 | 2021-2025 | Datroway, Enhertu, Injectafer |
| Genzyme Corporation | $242.46 | 2021-2025 | |
| Genentech USA, INC. | $236.78 | 2021-2025 | Venclexta, Phesgo, Perjeta |
| Astrazeneca Pharmaceuticals LP | $201.56 | 2021-2025 | Imfinzi, Lynparza |
| Glaxosmithkline, LLC. | $191.99 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Lilly USA, LLC | $186.70 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $172.62 | 2021-2025 | Tukysa, Adcetris, Padcev |
| Abbvie INC. | $156.87 | 2021-2025 | |
| Incyte Corporation | $135.97 | 2021-2025 | Zynyz, Niktimvo, Monjuvi |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $123.62 | 2024-2025 | |
| Mirati Therapeutics, INC. | $120.08 | 2023 | Krazati |
| Amgen INC. | $104.79 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $102.26 | 2021-2024 | Somatuline Depot, Onivyde |
| Regeneron Healthcare Solutions, INC. | $92.49 | 2021-2024 | Libtayo |
| Pharmaessentia USA Corporation | $91.08 | 2022-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $86.72 | 2023-2025 | Alunbrig, Fruzaqla |
| Novocure INC. | $85.51 | 2022-2024 | Optune, Optune Lua (Novottf-200t) |
| Tersera Therapeutics LLC | $80.92 | 2022-2025 | Zoladex, Quzyttir |
| Puma Biotechnology, INC. | $80.24 | 2021-2024 | |
| Taiho Oncology, INC. | $79.28 | 2024-2025 | |
| Eisai INC. | $74.67 | 2024-2025 | |
| Stemline Therapeutics INC. | $72.49 | 2023-2025 | Orserdu |
| Karyopharm Therapeutics INC. | $72.41 | 2022-2024 | Xpovio |
| Array Biopharma INC | $62.70 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Jazz Pharmaceuticals INC. | $60.79 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.01 | 2023-2024 | Gilotrif |
| G1 Therapeutics, INC. | $38.11 | 2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $36.77 | 2024 | Ultomiris |
| Legend Biotech USA INC. | $34.42 | 2025 | Carvykti |
| Astellas Pharma US INC | $34.06 | 2023-2025 | Vyloy, Padcev |
| Sobi, INC | $33.45 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $28.08 | 2024 | Qinlock |
| Acrotech Biopharma INC. | $27.30 | 2024 | Beleodaq |
| Gilead Sciences, INC. | $26.65 | 2024 | |
| Aveo Pharmaceuticals, INC. | $23.07 | 2025 | |
| Genmab U.S., INC. | $23.06 | 2024 | Tivdak |
| Beigene USA, INC. | $22.56 | 2024 | Brukinsa |
| Coherus Oncology, INC. | $21.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.46 | 2025 | |
| Dova Pharmaceuticals | $19.39 | 2021 | |
| Adc Therapeutics America, INC. | $18.04 | 2023 | |
| Beone Medicines USA, INC. | $16.53 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $16.34 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $15.98 | 2023 | Epkinly, Imbruvica |
| Azurity Pharmaceuticals, INC. | $15.07 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Bralley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.